Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 276.00
Bid: 271.00
Ask: 276.00
Change: -1.00 (-0.36%)
Spread: 5.00 (1.845%)
Open: 277.00
High: 280.00
Low: 274.00
Prev. Close: 277.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

DIRECTOR DEALINGS SUMMARY: Nostrum Chairman Sells 18.7 Million Shares

Thu, 02nd Apr 2015 14:02

Director Dealings Summary - Week Ended April 2        
Company Name Position Number of Shares Resulting Holding *Note GBP Value
             
BUYS            
RM2 International John Walsh CEO 1.2 million 22.2 million   648,000
London Capital Group Charles-Henri Sabet CEO 125,000 6.9 million   340,000
Hutchison China Simon To Chairman 18,000 69,000 Same day as concept trial for cancer treatment met efficacy target. 234,000
Hutchison China Edith Shih Non-Executive 18,000 48,000 Same day as concept trial for cancer treatment met efficacy target. 234,000
Standard Life UK Smaller Co's Allister Langlands  Director 50,000 95,000   145,000
Koovs Waheed Alli  Chairman 152,500 4.9 million Same day as Koovs said it would spend more on marketing than anticapted. 99,000
Walker Crips Sean Kin Wai Lam MD 221,000 422,996   95,000
Walker Crips Lim Hua Min Non-Executive 221,000 9.1 million   95,000
Monitise Elizabth Buse CEO 500,000 1 million One week after Monitise said it was no longer for sale  deciding to remain an independent company. 66,000
Stanley Gibbons Martin Bralsford Chairman 22,000 204,800 Same day as profit warning. 52,000
Diploma Andrew Smith Non-Executive 5,500 Undisclosed   45,000
Indivior Shaun Thaxter CEO 20,000 500,000   39,000
Monitise Tim Wade Non-Executive 250,000 350,000 One week after Monitise said it was no longer for sale  deciding to remain an independent company. 35,000
7digital Donald Cruickshank Chairman 140,000 290,000   24,000
Synectics David Coghlan Chairman 20,000 1.5 million   23,000
Plant Impact John Brubaker CEO 40,000 646,000   21,000
Mission Marketing David Morgan Chairman 40,000 6.1 million   17,000
PuriCore Charles Spicer Chairman 50,610 75,000   16,000
Inspirit Energy John Gunn CEO 2 million 355 million Same day as Inspirit said it will deliver its first micro-combined heat and power boiler to a major utility. 13,000
Barclays John McFarlane Incoming Chairman 5,000 6,015 Will become chairman at AGM on April 23. 12,000
LPA Goup Per Staehr Non-Executive 15,000 185,500   11,000
Progility Hugh Crawley CFO 200,000 200,000 Appointed last Friday. 11,000
superGroup Euan Sutherland CEO 10,117 11,613   9,900
Lavendon John Coghlan Non-Executive 5,000 5,500   9600
Aeorema Communications Michael Hale Chairman 25,000 1.7 million   6,900
Churchill China David Taylor CFO 1,000 21,000   6,000
SOCO International Anthony Maris COO 1,213 132,956   1,900
             
             
SELLS            
Nostrum Oil & Gas Frank Monstrey Chairman 18.7 million 32.5 million 2 days after Nostrum reported profit drop. 109,000,000
NAHL Group Samantha Porteous Non-Executive Director 3.1 million Nil 3 days after NAHL reported profit drop in maiden results. 7,600,000
IHG Tracy Robbins Director 28,047 183,997   738,000
Michael Page Oliver Watson Director 101,620 Undisclosed   540,000
Jupiter Fund Management Adrian Creedy Company Secretary 100,000 1.8 million   414,000
STV Group Rob Woodward CEO 100,000 419,322   383,000
Nichols Peter Nichols Chairman 17,060 2.1 million   201,000
Tribal Group Steve Breach Finance Director 81,296 172,728 2 weeks after Tribal swung to a loss. 120,000
Witan Investment Trust Harry Henderson Chairman 2,100 722,732   17,000
             
*Note: A recent company event around the time of the dealing does not suggest the dealing took place because of that event. When a spouse or related party to a director buys shares, the resulting holding is the beneficial holding of the director
 
             
Contact: +44 207 199 0340; newsroom@alliancenews.com; @AllNewsTeam      
             
Copyright 2015 Alliance News Limited. All Rights Reserved.        

More News
17 Nov 2020 19:31

IN BRIEF: Hutchison Chi-Med To Issue USD100 Million In Shares To CPP

IN BRIEF: Hutchison Chi-Med To Issue USD100 Million In Shares To CPP

Read more
17 Sep 2020 21:35

UK TRADING UPDATE SUMMARY: Hutchison China Drug Application Accepted

UK TRADING UPDATE SUMMARY: Hutchison China Drug Application Accepted

Read more
4 Sep 2020 14:13

Hutchison Chi-Med begins latest trial of fruquintinib

(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, said on Friday that it has initiated 'FRESCO-2' - a phase 3 registration study of 'fruquintinib' for the treatment of patients with metastatic colorectal cancer (CRC) in the US, Europe and Japan.

Read more
3 Sep 2020 21:27

IN BRIEF: Hutchison China Initiates Phase II Trial Of HMPL-453

IN BRIEF: Hutchison China Initiates Phase II Trial Of HMPL-453

Read more
10 Aug 2020 11:04

IN BRIEF: Hutchison Chi-Med Plans Surufatnib Marketing Application

IN BRIEF: Hutchison Chi-Med Plans Surufatnib Marketing Application

Read more
30 Jul 2020 17:56

IN BRIEF: Hutchison China Interim Loss Widens Despite Revenue Growth

IN BRIEF: Hutchison China Interim Loss Widens Despite Revenue Growth

Read more
28 Jul 2020 19:48

IN BRIEF: Hutchison China Amends License Agreement With Eli Lilly

IN BRIEF: Hutchison China Amends License Agreement With Eli Lilly

Read more
24 Jul 2020 15:45

Hutchison Chi-Med begins phase 1 study of 'HMPL-306'

(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, has initiated a phase 1 study of 'HMPL-306', it announced on Friday, in patients with hematological malignancies in China.

Read more
24 Jul 2020 14:33

Chi-Med Trials Dual Inhibitor For Hematological Cancer

Chi-Med Trials Dual Inhibitor For Hematological Cancer

Read more
23 Jul 2020 16:03

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
23 Jul 2020 16:02

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
25 Jun 2020 15:08

Hutchison China Gets USD100 Million From US Private Equity Firm

Hutchison China Gets USD100 Million From US Private Equity Firm

Read more
18 Jun 2020 16:46

IN BRIEF: Hutchison China Gets US FDA Fast Track For Cancer Drug

IN BRIEF: Hutchison China Gets US FDA Fast Track For Cancer Drug

Read more
18 Jun 2020 09:18

Hutchison Chi-Med gets FDA fast track approval for fruquintinib

(Sharecast News) - Hutchison China MediTech, trading as 'Chi-Med', announced on Thursday that the US Food and Drug Administration (FDA) has granted 'fast track designation' for the development of 'fruquintinib'.

Read more
9 Jun 2020 14:06

Hutchison Chi-Med venture to surrender unused land in Guangzhou

(Sharecast News) - Hutchison China MediTech, trading as 'Chi-Med', announced on Tuesday that Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company (HBYS) - its 50-50 joint venture with Guangzhou Baiyunshan Pharmaceutical Holdings - has agreed the planned return of its remaining 34 years land-use rights on its 30,000 square metre unused site in Tong He Town with the Guangzhou government.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.